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ABSTRACT
Background. Current literature is inconsistent in the associa-
tions between computed tomography (CT)-based body com-
position measures and adverse outcomes in older patients
with colorectal cancer (CRC). Moreover, the associations with
consecutive treatment modalities have not been studied.
This study compared the associations of CT-based body com-
position measures with surgery- and chemotherapy-related
complications and survival in older patients with CRC.
Materials and Methods. A retrospective single-center cohort
study was conducted in patients with CRC aged ≥65 years who
underwent elective surgery between 2010 and 2014. Gender-
speciﬁc standardized scores of preoperative CT-based skeletal
muscle (SM), muscle density, intermuscular adipose tissue
(IMAT), visceral adipose tissue (VAT), subcutaneous adipose
tissue, IMAT percentage, SM/VAT, and body mass index (BMI)
were tested for their associations with severe postoperative
complications, prolonged length of stay (LOS), readmission,
and dose-limiting toxicity using logistic regression and 1-year
and long-term survival (range 3.7–6.6 years) using Cox regres-
sion. Bonferroni correction was applied to account for multiple
testing.
Results. The study population consisted of 378 patients with
CRC with a median age of 73.4 (interquartile range 69.5–78.4)
years. Severe postoperative complications occurred in 13.0%,
and 39.4% of patients died during follow-up. Dose-limiting toxic-
ity occurred in 77.4% of patients receiving chemotherapy
(n = 53). SM,muscle density,VAT, SM/VAT, and BMIwere associ-
ated with surgery-related complications, and muscle density,
IMAT, IMAT percentage, and SM/VATwere associated with long-
term survival. After Bonferroni correction, no CT-based body
composition measure was signiﬁcantly associated with adverse
outcomes. Higher BMIwas associatedwith prolonged LOS.
Conclusion. The associations between CT-based body composi-
tion measures and adverse outcomes of consecutive treatment
modalities in older patients with CRC were not consistent or
statistically signiﬁcant. The Oncologist 2019;25:1–10
Implications for Practice: Computed tomography (CT)-based body composition, including muscle mass, muscle density, and
intermuscular, visceral, and subcutaneous adipose tissue, showed inconsistent and nonsigniﬁcant associations with surgery-
related complications, dose-limiting toxicity, and overall survival in older adults with colorectal cancer. This study under-
scores the need to verify whether CT-based body composition measures are worth implementing in clinical practice.
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Colorectal cancer (CRC) is a highly prevalent disease in older
individuals, representing more than 10% of all new cancer
cases worldwide [1]. The cornerstone of CRC treatment is sur-
gical resection, potentially preceded by neoadjuvant (chemo)
radiation in rectal cancer or followed by adjuvant chemother-
apy in patients with high-risk stage II and stage III colon cancer
[2]. Older patients with CRC are known to have a higher risk of
adverse outcomes such as postoperative complications,
prolonged length of stay (LOS), dose reductions and early dis-
continuation of chemotherapy, and higher overall and cancer-
related mortality compared with younger patients [3–6].
Computed tomography (CT)-based body composition mea-
sures, and especially skeletal muscle mass (SM), muscle den-
sity, which is a measure of muscle quality determined by fat
inﬁltration [7], and visceral adipose tissue (VAT), have been
proposed as predictors of adverse outcomes in older patients
with CRC [8–12]. However, although several studies have rev-
ealed an association between SM and severe or infectious
postoperative complications [11, 13], a lack of association with
severe postoperative complications was found in other studies
[9, 10, 14]. Muscle density was found to be associated with
long-term overall survival [15–17], in contrast to other studies
[9–11]. For VAT, the association with prolonged LOS showed
both positive and negative results [18]. Therefore, it remains
to be proved if CT-based body composition measures show
consistent and statistically signiﬁcant associations with adverse
outcomes in older patients with CRC to be clinically relevant.
Moreover, the predictive value of CT-based body composition
measures on consecutive treatment modalities including both
surgery- and chemotherapy-related complications within the
same cohort of (older/CRC) cancer patients has not been
reported yet.
The aim of this study was to compare CT-based body
composition measures regarding their predictive value of
adverse outcomes in older patients with CRC, including
surgery-related complications, dose-limiting chemotherapy
toxicity, and overall survival.
MATERIALS AND METHODS
Study Population
This is a retrospective single-center cohort study evaluating
the PREdictive value of MUScle mass in CoLorectal cancer in
Elderly (PREMUSCLE), in patients with primary CRC aged
65 years and older who underwent elective surgery between
2010 and 2014 at Medical Spectrum Twente, a large non-
academic teaching hospital in The Netherlands. The study
population of 472 older patients with CRC was selected from
the Dutch ColoRectal Audit (DCRA), which contains prospec-
tively collected information on patient and tumor characteris-
tics, treatment, and outcomes of CRC surgery. Patients were
excluded if (a) there were two or more primary tumors requir-
ing surgery (n = 41); (b) pathology reports concluded the pri-
mary tumor was benign or noncolorectal (n = 12); (c) surgery
was classiﬁed as acute, urgent, or elective after stent place-
ment because of an increased risk of complications (n = 4);
(d) data on body height and/or weight were missing (n = 4);
(e) data on outcome measures were missing (n = 1); (f) there
was no preoperative CT scan available on the level at the third
lumbar vertebra (L3; n = 14); or (g) CT scan was not eligible
for analysis because of quality issues such as artifacts or frame
selection (n = 18). This led to the inclusion of 378 older
patients with CRC, as is shown in Figure 1. Patient data were
retrieved from the DCRA and hospital information system and
included gender, age, body weight, height, preoperative num-
ber of comorbidities and medications (both retrieved by medi-
cal record review), Karnosfky Performance Scale score (range
0–100), tumor- and treatment-related characteristics, and
predeﬁned outcome measures. Survival data were extracted
from the civil registry. The study has been approved by the
Medical Ethics Committee of the Amsterdam University Medi-
cal Center, location VU Medical Center, with site-speciﬁc
approval of Medical Spectrum Twente.
CT-Based Body Composition
Body composition was measured by analyzing single-slice
abdominal CT scans at L3 that were obtained preoperatively
for staging purposes. Single-slice CT scan analysis was per-
formed because SM area and adipose tissue area at L3 are
highly correlated with total body SM and total body adipose
tissue volume [19, 20]. CT scans were analyzed using medical
imaging software SliceOMatic version 5.0 (TomoVision, Mon-
treal, QC, Canada), which identiﬁes body tissues based on
the Hounsﬁeld Units (HU). CT scan analyses were performed
by a trained and certiﬁed researcher (S.L.). Imaging quality
was assessed on the identiﬁcation of the following muscles:
rectus abdominis, transversus abdominis, internal and exter-
nal oblique, quadratus lumborum, erector spinae, and psoas.
In case of unilateral quality issues in a symmetrical image,
unilateral body composition area was determined and multi-
plied by two. CT scans in which total SM could not be deter-
mined were excluded. A second assessor was consulted in
case of doubt (n = 15) about inclusion or multiplication of
body composition area (W.L.). Tissues were identiﬁed by HU
ranges: SM −29 to +150 HU; intermuscular adipose tissue
(IMAT) and subcutaneous adipose tissue (SAT) −190 to −30
HU; VAT −150 to −50 HU [20, 21]. Total cross-sectional sur-
face area in cm2 of each tissue was computed by multiplying
the pixel area with the amount of pixels. Skeletal muscle index
(SMI) was calculated by dividing SM (cm2) by height2 (m2).
The percentage of IMAT was calculated as a measure of fat-
tiness of the muscle by IMAT/(IMAT+SM)*100; the ratio
between SM and VAT as a measure of sarcopenic obesity.
Muscle density was determined by the mean HU of muscle tis-
sue, lower HU is a sign of more fat inﬁltration within the muscle
[7]. Median tube potential of CT scans was 120 kilovolts (range
100–135 kilovolts), and slice thickness was 3 millimeters (range
1–5 millimeters). All contrast-enhanced CT scans were used.
The intra- and interobserver correlation coefﬁcient for variabil-
ity of body composition measures were calculated using a
two-way mixed model with absolute agreement. Intraobserver
correlation coefﬁcient for variability was 0.991–1.000 based on
a random selection of n = 10, and interindividual correlation
coefﬁcient for variability was 0.971–1.000 based on a random
selection of n = 24 (A.V.).
© 2019 The Authors.
The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
CT-Based Body Composition and Adverse Outcomes2
Published Ahead of Print on November 20, 2019 as 10.1634/theoncologist.2019-0590. 










Based on the Tumor, Node, Metastasis classiﬁcation, all
patients were postoperatively classiﬁed into a cancer stage
according to the American Joint Committee on Cancer guide-
lines [22]. Patients with high-risk stage II and stage III colon
cancer were considered for adjuvant chemotherapy treat-
ment [2], which consisted of folinic acid, ﬂuorouracil and
oxaliplatin, capecitabine and oxaliplatin, capecitabine mon-
otherapy, or folinic acid and ﬂuorouracil according to national
guidelines. Equivalent variables were used to identify patients
with high-risk stage II colon cancer in that era: (a) T4 tumor;
(b) less than 10 lymph nodes found; (c) venous vascular or
lymph invasion of the tumor; (d) poorly differentiated tumor;
and (e) preoperative obstruction or perforation of the colon
or rectum. Dihydropyrimidine dehydrogenase deﬁciency was
not taken into consideration because this was not routinely
tested in The Netherlands at the time of the study. A multi-
disciplinary team including a gastroenterologist, gastrointesti-
nal surgeon, radiologist, radiotherapist, and medical oncologist
decided whether a patient would be referred to the medical
oncology department to discuss adjuvant chemotherapy treat-
ment. If so, patients were directed to the medical oncologist,
who decided together with the patient on the initiation of
adjuvant chemotherapy treatment.
Outcome Measures
Surgery-related complications included severe postoperative
complications, prolonged LOS, and readmission. Severe postop-
erative complications were deﬁned as any grade 3 (requiring
reintervention), grade 4 (requiring intensive care unit admit-
tance), or grade 5 (death) surgical or medical complication
according to the Clavien-Dindo Classiﬁcation of Surgical
Complications, during admission or within 30 days after surgery
[23]. Surgical complications included anastomotic leakage,
intra-abdominal abscess, wound or fascial dehiscence, stoma-
related complications, blood loss >500 milliliters or postopera-
tive hemorrhage, incisional hernia, bowel injury, or injury to
another organ. Medical complications included respiratory, car-
diac, thromboembolic, infectious, neurological, and other com-
plications. LOS was calculated as the number of days between
the day of surgery until the day of discharge after surgery and
dichotomized into LOS ≤14 days and prolonged LOS of >14 days
because prolonged LOS is associated with postoperative com-
plications [24]. Readmissions included readmission to the hos-
pital for any reason within 30 days after discharge.
Chemotherapy-related outcome for the subgroup receiv-
ing adjuvant chemotherapy was deﬁned as dose-limiting
toxicity, which was chemotherapy toxicity that led to a dose
reduction or early discontinuation.
Survival was deﬁned as 1-year and long-term overall
survival, with a median follow-up of 5.3 (interquartile range
[IQR] 3.7–6.6) years. Survival time was calculated from the
day of surgery until the day of death of any cause (died) or
the April 23, 2019 (censored).
Statistical Analyses
Variables are described by number (percentage), mean SD,
or median (IQR). To avoid dichotomization of the determi-
nants by using cutoff points, CT-based body composition
measures (SM, SMI, muscle density, IMAT, VAT, SAT, IMAT
percentage, and SM/VAT) and body mass index (BMI) were
analyzed continuously, using gender-speciﬁc standardized
Z scores to enable comparison of the body composition
measures. Variables that were not normally distributed
Figure 1. Flowchart of selection of patients.
Abbreviations: CRC, colorectal cancer; CT, computed tomography.
© 2019 The Authors.
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Table 1. Patient characteristics for all patients and stratiﬁed by adjuvant chemotherapy treatment
Characteristics All patients (n = 378) Received chemotherapy (n = 53)
Demographics
Gender, male 228 (60.3) 30 (56.6)
Age, median (IQR), years 73.4 (69.5–78.4) 70.9 (67.5–73.5)
Comorbidity, median (IQR), n 2.0 (1.0–3.0) 1.0 (1.0–2.5)
Medication, median (IQR), n 4.0 (2.0–6.5)a 2.0 (1.0–4.0)
Karnofsky score, ≥90 173 (51.2)b 39 (75.0)c
Tumor characteristics
Primary tumor, colon 284 (75.1) 53 (100.0)
Tumor stage, colon cancer 284 53
Stage I 56 (19.7) —
Stage II, low-risk 54 (19.0) —
Stage II, high-risk 42 (14.8) 1 (1.9)
Stage III 96 (33.8) 52 (98.1)
Stage IV 26 (9.2) —
Stage T0/unknown 10 (3.6) —
Tumor stage, rectum cancer 94
Stage I 34 (36.2) —
Stage II 22 (23.4) —
Stage III 20 (21.3) —
Stage IV 4 (4.3) —
Stage T0/unknown 14 (14.9) —
Body composition
Body weight, mean  SD, kg 79.2  14.4 82.7  13.7
Height, mean  SD, cm 170.7  9.0 172.5  7.8
BMI, mean  SD, kg/m2 27.1  4.1 27.7  3.7
SM, mean  SD, cm2 129.1  29.7 138.7  33.1
SMI, mean  SD, cm2/m2 44.0  8.1 46.3  8.9
Muscle density, mean  SD, HU 31.2  8.0 32.4  7.5
IMAT, median (IQR), cm2 13.2 (9.1–19.7) 14.4 (10.0–18.2)
VAT, mean  SD, cm2 193.9  107.3d 204.0  117.0
SAT, median (IQR), cm2 172.6 (126.9–220.5)e 180.6 (133.2–217.0)f
IMAT, median (IQR), % 9.3 (6.7–14.4) 9.1 (6.4–12.3)
SM/VAT, median (IQR), cm2 0.7 (0.5–1.1)d 0.7 (0.5–1.2)
Surgery
Surgical approach, laparoscopic 217 (57.4) 39 (73.6)
Postoperative complication <30 days 180 (47.6) 21 (39.6)
Severe postoperative complication 49 (13.0) 5 (9.4)
LOS, median (IQR), days 6.5 (5.0–11.0) 5.0 (4.0–7.5)
Prolonged LOS, ≥14 days 56 (14.8) 5 (9.4)
Readmission <30 days 46 (12.2) 4 (7.5)
Chemotherapy
Chemotherapeutic agent 53
Capecitabine — 26 (49.1)
CAPOX — 23 (43.4)
FOLFOX — 1 (1.9)
5FU/LV — 3 (5.7)
Toxicity, all grade — 46 (86.8)
Dose reduction — 28 (52.8)
(continued)
© 2019 The Authors.
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were log-transformed before standardization (IMAT, SAT,
IMAT percentage, and SM/VAT). The associations between
gender-speciﬁc standardized body composition measures and
treatment-related adverse outcomes were analyzed using bivar-
iate logistic regression for severe postoperative complications,
prolonged LOS, readmission, and dose-limiting toxicity and Cox
proportional hazards model for 1-year and long-term overall
survival. For survival analyses, survival time in months was used.
All analyses were performed using a crude model and an
adjusted model for age, stage of disease, and number of medi-
cations (model 1) to adjust for possible confounders. Stage of
disease was considered because of its association with cachexia
[25] and cancer-related outcomes. Number of medications was
considered as a reﬂection of overall health and severity of the
number of comorbidities that could inﬂuence both body compo-
sition and the risk of adverse outcomes [26]. The associations
between SM and SMI and adverse outcomes were additionally
adjusted for BMI ≥30 kg/m2 (model 2), to eliminate the potential
inﬂuence of sarcopenic obesity. The cutoff BMI ≥30 kg/m2 was
chosen because it was identiﬁed as an independent predictor
of complicated postoperative course in patients with CRC in The
Netherlands [27]. Owing to the number of determinant vari-
ables (9) and outcome measures (6) that were tested, a
Bonferroni correction for 54 tests was applied to avoid type
1 errors. Therefore, p values of <.001 were considered statisti-
cally signiﬁcant. Sensitivity analyses were performed on the
possible impact of (a) the time interval between CT scan
and surgery, by excluding CT scans made more than 8 weeks
before surgery (analyses with n = 304); (b) estimations based on
unilaterally determined body composition area, by excluding CT
scans in which surface area was multiplied (n = 352); and
(c) stratiﬁcation of colon cancer (n = 284) and rectum cancer
(n = 94). Post hoc analyses were performed to clarify associa-
tions, by stratifying for Karnofsky Performance Scale score based
on the median of the study population, ≤80 (n = 165) and ≥ 90
(n = 173). Statistical analyses were performed using IBM SPSS
Statistics version 25 (IBM SPSS Statistics, Feltham, U.K.).
RESULTS
Patient Characteristics
The study population of 378 older patients with CRC consisted
of 284 with colon cancer (75.1%) and 94 with rectal cancer
(24.9%). The median age of the total cohort was 73.4 (IQR
69.5–78.4) years, and 228 patients were male (60.3%). In total,
13.0% of all patients experienced a severe postoperative com-
plication, prolonged LOS occurred in 14.8%, and 12.2% of
patients were readmitted to the hospital within 30 days after
discharge. After 1-year and more than 5-years of follow-up,
6.9% and 39.4%, respectively, of patients had died. The sub-
group of patients who had an indication for adjuvant chemo-
therapy consisted of 138 patients with high-risk stage II or
stage III colon cancer (36.5%). In 53 of these patients, of
whom 1 had high-risk stage II colon cancer, adjuvant chemo-
therapy was initiated (38.4%). Reasons for not initiating adju-
vant chemotherapy were decision by the medical oncologist
or multidisciplinary team, patients’ preference, or both. Of
53 patients with colon cancer, 41 (77.4%) treated with adju-
vant chemotherapy experienced dose-limiting toxicity. Patient
characteristics of the total cohort and the subgroup of patients
who received adjuvant chemotherapy are shown in Table 1.
Surgery-Related Complications and Dose-Limiting
Toxicity
Table 2 shows the associations between gender-speciﬁc stan-
dardized body composition measures and severe postopera-
tive complications, prolonged LOS, readmission, and dose-
limiting toxicity. Higher SM and SMI were associated with a
higher risk of readmission, and higher SM was associated with
prolonged LOS in the adjusted models. Lower muscle density
was associated with severe postoperative complications in the
adjusted model. Higher VAT was associated with a higher risk
of severe postoperative complications, prolonged LOS, and
readmission. Higher SM/VAT was associated with a lower risk
of prolonged LOS and readmission. Higher BMI was associated
with a higher risk of severe postoperative complications and
prolonged LOS. BMI showed the strongest association of all
body composition measures with severe postoperative com-
plications and prolonged LOS. VAT was most strongly associ-
ated with the risk of readmission. After applying Bonferroni
correction, BMI remained statistically signiﬁcant in its associ-
ation with prolonged LOS in the crude model. None of the
body composition measures showed a signiﬁcant association
with dose-limiting toxicity in crude or adjusted analyses.
One-Year and Long-Term Overall Survival
None of the body composition measures were associated with
1-year overall survival. For long-term overall survival, muscle
density was associated with a lower mortality risk whereas IMAT
and IMAT percentage were associated with a higher mortality
Table 1. (continued)
Characteristics All patients (n = 378) Received chemotherapy (n = 53)
Early discontinuation — 26 (49.1)
Dose-limiting toxicity — 41 (77.4)
Survival
One-year overall survival, died 26 (6.9) 2 (3.8)
Long-term overall survival, died 149 (39.4) 18 (34.0)
All variables are presented in n (%) unless otherwise indicated. The subgroup of patients undergoing chemotherapy consisted of patients with
high-risk stage II and stage III colon cancer.
Data available of an = 373; bn = 338; cn = 52; dn = 376; en = 310; and fn = 41.
Abbreviations: 5FU, ﬂuorouracil; BMI, body mass index; CAPOX, capecitabine and oxaliplatin; FOLFOX, folinic acid, ﬂuorouracil, and oxaliplatin;
HU, Hounsﬁeld units; IMAT, intermuscular adipose tissue; IQR, interquartile range; LOS, length of stay; LV, leucovorin (folinic acid); SAT, subcuta-
neous adipose tissue; SM, skeletal muscle; SMI, skeletal muscle index; VAT, visceral adipose tissue.
© 2019 The Authors.
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risk. The association was strongest for IMAT compared with
other body composition measures. In the subgroup of patients
who received adjuvant chemotherapy, SM/VAT was associated
with a higher mortality risk during follow-up in the adjusted
model. None of the survival analyses remained statistically sig-
niﬁcant after Bonferroni correction, as is shown in Table 3.
Sensitivity Analyses
The median number of days between CT scan and surgery was
36 days (range 8–209 days), with 80.4% of patients having a
CT scan that was made a maximum of 8 weeks before surgery.
Sensitivity analyses excluding CT scans that were made more
than 8 weeks before surgery (supplemental online Table 1)
and excluding scans in which body composition area was mul-
tiplied because of quality issues (supplemental online Table 2)
showed results consistent with the total cohort. Stratiﬁcation
for colon and rectum cancer (supplemental online Tables 3, 4)
showed similar results for both tumor types. Post hoc analyses
stratiﬁed by Karnofsky Performance Scale score were per-
formed to clarify the associations between higher SM and SMI









complications LOS > 14 days Readmission Dose-limiting toxicity
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Z SM, cm2
Crude 1.255 0.936–1.681 1.253 0.949–1.654 1.445a 1.071–1.950 0.722 0.405–1.287
Model 1 1.309 0.942–1.819 1.452a 1.054–2.002 1.532a 1.097–2.140 0.676 0.360–1.270
Model 2 1.315 0.938–1.844 1.434a 1.033–1.991 1.603a 1.130–2.275 0.604 0.299–1.219
Z SMI, cm2/m2
Crude 1.118 0.833–1.502 1.175 0.890–1.550 1.463a 1.089–1.965 0.634 0.350–1.146
Model 1 1.169 0.851–1.605 1.327 0.980–1.798 1.503a 1.096–2.062 0.603 0.320–1.139
Model 2 1.171 0.842–1.627 1.308 0.954–1.793 1.602a 1.145–2.242 0.518 0.249–1.076
Z Muscle density, HU
Crude 0.740 0.546–1.002 0.759 0.570–1.011 0.850 0.624–1.157 0.669 0.337–1.331
Model 1 0.684a 0.486–0.962 0.773 0.561–1.066 0.884 0.633–1.235 0.564 0.259–1.229
Z IMAT, cm2
Crude 1.291 0.949–1.758 1.280 0.956–1.712 1.162 0.850–1.589 1.263 0.578–2.758
Model 1 1.366 0.980–1.902 1.297 0.947–1.777 1.130 0.817–1.563 1.340 0.586–3.065
Z VAT, cm2
Crude 1.341a 1.007–1.787 1.458a 1.111–1.914 1.551a 1.157–2.078 0.968 0.529–1.772
Model 1 1.355 0.996–1.845 1.465a 1.096–1.960 1.543a 1.137–2.093 1.005 0.539–1.872
Z SAT, cm2
Crude 0.996 0.711–1.394 1.283 0.914–1.802 1.195 0.839–1.703 1.532 0.597–3.929
Model 1 1.139 0.768–1.690 1.224 0.851–1.762 1.104 0.762–1.599 1.561 0.624–3.906
Z IMAT, %
Crude 1.145 0.843–1.557 1.150 0.860–1.537 1.007 0.739–1.372 1.445 0.699–2.989
Model 1 1.203 0.861–1.680 1.121 0.816–1.539 0.977 0.705–1.355 1.572 0.722–3.425
Z SM/VAT, cm2
Crude 0.794 0.564–1.116 0.647a 0.454–0.922 0.605a 0.406–0.902 0.904 0.443–1.842
Model 1 0.716 0.480–1.069 0.650a 0.440–0.961 0.600a 0.390–0.923 0.831 0.388–1.777
Z BMI, kg/m2
Crude 1.343a 1.017–1.774 1.541 1.182–2.010 1.172 0.874–1.572 0.932 0.454–1.913
Model 1 1.357 0.998–1.845 1.571a 1.174–2.103 1.072 0.781–1.471 0.966 0.468–1.994
Body composition was analyzed with gender-speciﬁc standardized scores. Severe postoperative complications were deﬁned as (0) no or grade 1–2
Clavien-Dindo complications; (1) grade 3–5 Clavien-Dindo complications (complications that led to reintervention, intensive care unit admittance,
or death). Dose-limiting toxicity was deﬁned as (0) no toxicity or no toxicity that led to dose reduction or early discontinuation of chemotherapy;
(1) toxicity that led to dose reduction or early discontinuation of chemotherapy.
Model 1: adjusted for age, stage and number of medications. Dose-limiting toxicity was adjusted for age and number of medications. Model 2:
+ BMI ≥30 kg/m2.
Bolded values (p < .001) are considered statistically signiﬁcant after Bonferroni correction.
ap < .05.
Abbreviations: BMI, body mass index; CI, conﬁdence interval; HU, Hounsﬁeld units; IMAT, intermuscular adipose tissue; LOS, length of stay;
OR, odds ratio; SM, skeletal muscle; SMI, skeletal muscle index; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.
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and higher risk of prolonged LOS and readmission (supple-
mental online Table 5). The associations between SM and SMI
and higher risk of readmission were only present in the group
with a Karnofsky Performance Scale score of ≥90.
DISCUSSION
In a population of older patients with CRC, preoperative
CT-based body composition measures were not consistently or
statistically signiﬁcantly associated with surgery-related compli-
cations, dose-limiting toxicity, and overall survival. SM, muscle
density, VAT, SM/VAT, and BMI showed associations with
surgery-related complications. Muscle density, IMAT, and IMAT
percentage showed associations with long-term overall survival
in the total cohort and SM/VAT in the subgroup of patients
receiving adjuvant chemotherapy. However, associations of CT-
based body composition measures were no longer statistically
signiﬁcant after Bonferroni correction for multiple testing was
applied. The only statistically signiﬁcant association was the
association of higher BMI with prolonged LOS. The results of
this study underscore the need for a meta-analysis to elucidate
the value of CT-based body composition measures to predict
adverse outcomes in patients with CRC.
The current body of evidence shows inconsistent associa-
tions between body composition measures and adverse out-
comes in patients with CRC. Low SM has been shown to be
associated with severe postoperative complications [11], LOS
[13], dose-limiting toxicity [28–31], and long-term survival
[10, 14–17, 32–34]. However, other studies did not show
associations between low SM and overall [9–11, 14, 35–37]




One-year survival Long-term survival
All patients (n = 378) All patients (n = 378) Received chemotherapy (n = 53)
HR 95% CI HR 95% CI HR 95% CI
Z SM, cm2
Crude 0.753 0.498–1.138 0.976 0.834–1.142 0.861 0.561–1.320
Model 1 0.820 0.518–1.298 1.069 0.897–1.273 0.882 0.563–1.381
Model 2 0.832 0.523–1.325 1.125 0.936–1.351 0.900 0.566–1.430
Z SMI, cm2/m2
Crude 0.706 0.463–1.076 0.953 0.812–1.119 0.861 0.557–1.332
Model 1 0.780 0.494–1.232 0.998 0.840–1.187 0.879 0.560–1.379
Model 2 0.793 0.498–1.263 1.054 0.879–1.264 0.898 0.561–1.436
Z Muscle density, HU
Crude 0.687 0.470–1.006 0.814a 0.694–0.955 0.948 0.559–1.607
Model 1 0.786 0.511–1.209 0.918 0.771–1.093 0.957 0.544–1.686
Z IMAT, cm2
Crude 1.239 0.838–1.833 1.225a 1.039–1.444 1.161 0.622–2.165
Model 1 1.074 0.702–1.643 1.087 0.915–1.293 1.177 0.626–2.210
Z VAT, cm2
Crude 1.060 0.724–1.552 0.998 0.849–1.173 0.618 0.363–1.052
Model 1 0.984 0.639–1.515 0.941 0.792–1.118 0.593 0.338–1.042
Z SAT, cm2
Crude 0.997 0.657–1.514 0.934 0.785–1.111 0.789 0.368–1.694
Model 1 0.902 0.561–1.450 0.902 0.742–1.098 0.764 0.378–1.546
Z IMAT, %
Crude 1.317 0.881–1.969 1.205a 1.021–1.423 1.210 0.690–2.124
Model 1 1.111 0.719–1.715 1.049 0.879–1.252 1.198 0.679–2.112
Z SM/VAT, cm2
Crude 0.864 0.564–1.324 0.995 0.844–1.174 1.588 0.951–2.651
Model 1 1.025 0.647–1.622 1.131 0.951–1.345 1.778a 1.002–3.156
Z BMI, kg/m2
Crude 0.951 0.638–1.417 0.988 0.835–1.169 0.834 0.470–1.481
Model 1 0.836 0.529–1.320 0.899 0.744–1.087 0.840 0.470–1.501
Body composition was analyzed with gender-speciﬁc standardized scores. The hazard ratio for death is given; survival time was calculated in months.
Model 1: adjusted for age, stage, and number of medications. Associations with subgroup that received chemotherapy was adjusted for age and
number of medications. Model 2: + BMI ≥30 kg/m2.
ap < .05.
Abbreviations: BMI, body mass index; CI, conﬁdence interval; HR, hazard ratio; HU, Hounsﬁeld units; IMAT, intermuscular adipose tissue;
SAT, subcutaneous adipose tissue; SM, skeletal muscle; SMI, skeletal muscle index; VAT, visceral adipose tissue.
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or severe postoperative complications [9, 10, 14], readmission
[13], and long-term survival [9, 11]. These varying results may
have been caused by the use of different cutoff points, limit-
ing comparison of studies. Another explanation for the incon-
sistency in the literature could be the inclusion of all age
groups, as only one study speciﬁcally included older patients
and found a signiﬁcant association between low muscle mass
and overall survival in patients with rectal cancer receiving
chemoradiation [34]. The association between CT-based body
composition measures and adverse outcomes is expected to
differ between younger and older populations as body com-
position measures are negatively affected by age [38] but still
show inconsistency when only studies with a mean/median
age of 65 years and older are considered. In this study, statis-
tically signiﬁcant associations between higher SM and higher
risk of surgery-related complications were found before
Bonferroni correction was applied. This was contrary to what
was expected. Post hoc analyses revealed that these associa-
tions were mainly applicable in patients with a high Karnofsky
Performance Scale score. This could indicate that patients
with higher SM were treated more aggressively, leading to
a higher risk of surgery-related complications. Another possi-
bility is that these patients lost muscle mass prior to the pre-
operative CT scan, leading to higher risk of complications;
however, this could not be proved owing to the design of this
study. Potential inﬂuences of confounding factors, type of
treatment and type of complications, or edema leading to an
overestimation of muscle mass have been evaluated but
could not further explain the unexpected association between
higher SM and higher risk of surgery-related complications.
On the contrary, higher SM/VAT was associated with lower
risk of surgery-related complications before Bonferroni correc-
tion, which might imply that different body composition mea-
sures are needed to predict adverse outcomes than absolute
muscle mass. After accounting for multiple testing, neither SM
nor SM/VAT were signiﬁcantly associated with surgery-related
complications, dose-limiting toxicity, or overall survival.
Besides muscle mass, several CT-based adipose measures
were considered, including muscle density, IMAT, and VAT.
Based on the negative effects that low muscle density and
high IMAT and VAT can impose on the body, associations
with adverse outcomes were expected. The negative effect
of VAT, in contrast to SAT, is caused by provoked insulin
resistance and pro-inﬂammatory cytokines, which increases
the risk of detrimental health outcomes [39, 40]. IMAT, on
the other hand, which includes both inter- and intramuscular
fat [41], results in a misbalance in pro- and anti-inﬂammatory
cytokines, which can lead to a higher risk of adverse health
outcomes independent of VAT [42]. IMAT, in its turn, highly
correlates with muscle density, which is a measure of fat
inﬁltration in skeletal muscle ﬁbers [7]. Low muscle density
has been associated with reduced muscle strength and physi-
cal performance, which are determinants of adverse out-
comes in older patients [43, 44]. However, although muscle
density, IMAT, and VAT appeared to be associated with
adverse outcomes in this study, the associations were weak
and no longer present after correction for multiple testing.
This inconsistency is in line with available literature. Low
muscle density has been associated with postoperative com-
plications [9–11, 37] and long-term survival [15–17], although
other studies have found no associations with overall [35] or
severe postoperative complications [10] and long-term sur-
vival [9–11, 17]. The same counts for VAT or visceral obesity,
which was found to be associated with postoperative compli-
cations [36, 45–48], LOS [36, 46, 48], readmission [49], and
2-year survival [50] in some studies. However, in other stud-
ies, associations with overall postoperative complications
[35, 51], LOS [45, 47, 51, 52], readmission [36], dose-limiting
toxicity [29], and long-term survival [16, 33, 51, 53] were not
found. The use of cutoff points and inclusion of all age
groups could have contributed to the inconsistency of these
results. BMI was the only body composition measure that
remained statistically signiﬁcant after Bonferroni correction
and was associated with prolonged LOS. This can be explained
by the higher risk of surgical complications such as fascial
dehiscence and surgical incisional site infections and thrombo-
embolic complications in patients with higher BMI [27, 54].
These are complications that could have been classiﬁed as
mild complications (grade 1 or 2) because they do not neces-
sarily lead to reintervention but can still lead to longer LOS.
Apart from looking at CT-based body composition at one
moment in time, changes in body composition over time
might be important. A few studies have shown that body
composition in patients with CRC is dynamic and loss of mus-
cle and visceral fat tissue can lead to a higher risk of adverse
outcomes [55–58]. Furthermore, muscle function might be
more relevant than absolute mass, as has been shown in a
recent study in older patients with advanced cancer in which
higher muscle strength was associated with overall survival
whereas SM and muscle density were not [59]. An earlier
study showed that a combination of CT-based low SM, hand-
grip strength, and gait speed was predictive of postoperative
complications in patients with CRC [60]. Possibly, CT-based
body composition measures need to be combined with func-
tional measures such as handgrip strength and physical per-
formance to predict relevant patient outcomes. Moreover,
other domains of the Comprehensive Geriatric Assessment
such as nutritional status and cognition have prognostic value
and could contribute to the prediction of adverse outcomes
in older patients with CRC [61]. Future research needs to clar-
ify the prognostic value of these measures in addition to
CT-based body composition measures over time, to predict
the risk of adverse outcomes in older patients with CRC. This
is also important in the development of preoperative inter-
ventions, also known as prehabilitation, which can be effec-
tive in older patients with CRC [62, 63].
The strength of this study is the comparison of the associa-
tions of various standardized CT-based body composition mea-
sures on consecutive treatment modalities in older patients
with CRC. By omitting cutoff points and using gender-speciﬁc
standardized Z scores, body composition measures could be
compared with one another. Limitations of this study are that
it is a single-center cohort study and may not be representative
for other populations. Moreover, because of the retrospective
design, other prognostic measures such as nutrition and physi-
cal performance could not be taken into account. The sub-
group of patients receiving adjuvant chemotherapy was small,
resulting in limited power, and only included patients who
were considered ﬁt enough for chemotherapy treatment by
the multidisciplinary team, and almost half of all patients
© 2019 The Authors.
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received capecitabine monotherapy. Concerning the CT scans,
the time period between preoperative CT scan and surgery
and chemotherapy was not standardized, although sensitivity
analyses showed similar results excluding CT scans with a lon-
ger time period before surgery. A small proportion of 5% of CT
scans was not suitable for body composition measurement
because of artifacts or frame selection.
CONCLUSION
In a cohort of older patients with CRC, associations between
preoperative CT-based body composition measures and
surgery-related complications, dose-limiting toxicity, and over-
all survival were not consistent or statistically signiﬁcant. Asso-
ciations between CT-based body composition measures and
consecutive treatment modalities could not be conﬁrmed.
Future research should focus on the change in body composi-
tion over time combined with muscle strength, physical per-
formance, and other geriatric domains to predict adverse
outcomes in older patients with CRC.
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